NCT01009840 2014-09-25
IV Busulfan Plus Bortezomib Conditioning Regimen for Second Autologous Stem Cell Transplant in Multiple Myeloma Patients
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 2 Completed
Otsuka Pharmaceutical Development & Commercialization, Inc.
Texas Oncology Cancer Center